Share This Article:

Oxaliplatin induced hyperexcitability syndrome in patient with appendiceal adenocarcinoma

Abstract Full-Text HTML XML Download Download as PDF (Size:31KB) PP. 236-238
DOI: 10.4236/crcm.2013.24064    3,183 Downloads   4,284 Views  


Oxaliplatin is a novel platinum compound with clinical activity against several solid tumors. It has been associated with sensory neuropathies and, rarely, a neuromyotonia-like hyperexcitability syndrome; a form of peripheral neuropathy manifested by tremor and twitching activity of muscles. We present a case of hyperexcitability syndrome developed during the treatment of stage III appendiceal adenocarcinoma with oxaliplatin-containing regimen and was successfully treated with Pregabalin.

Cite this paper

Jabbour, N. , Alchreiki, M. and Hussain, M. (2013) Oxaliplatin induced hyperexcitability syndrome in patient with appendiceal adenocarcinoma. Case Reports in Clinical Medicine, 2, 236-238. doi: 10.4236/crcm.2013.24064.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] [1] Saif, M.W. and Reardon, J. (2005) Management of oxaliplatin-induced peripheral neuropath. Journal of Therapeutics and Clinical Risk Management, 1, 249-258.
[2] De Gramont, A., Figer, A., Seymour, M., et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology, 18, 2938-2947.
[3] Bleigberg, H. and De Gramont, A. (1998) Oxaliplatin plus 5-fluororuacil: Clinical experience in patients with advanced colorectal cancer. Seminars in Oncology, 25, 32-39.
[4] Saif, M.W. and Hashmi, S. (2008) Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemotherapy and Pharmacology, 61, 349-354. doi:10.1007/s00280-007-0584-7
[5] Lahrmann, H., Albercht, G., Drlicek, M., Oberndorfer, S., Urbanits, S., Wanschitz, J., et al. (2001) Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin’s lymphoma disease. Muscle & Nerve, 24, 834-838. doi:10.1002/mus.1078
[6] Fort, F., Pretegiani, E., Battisti, C., Sicurelli, F. and Federico, A. (2009) Neuromyotonia as paraneoplastic manifestation of bladder canrcinoma. Journal of the Neurological Sciences, 280, 111-112. doi:10.1016/j.jns.2009.01.022
[7] Leonard, G.D., Wright, M.A., Quinn, M.G., Fioravanti, S., Harold, N., Schuler, B., et al. (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer, 5, 116. doi:10.1186/1471-2407-5-116
[8] Auger, R.G. (1994) AAEM minimonograph: Diseases associated with excess motor unit activity. Muscle & Nerve, 17, 1250-1263. doi:10.1002/mus.880171103
[9] Reeback, J., Benton, S., Swash, M. and Schwartz, M.S. (1979) Penicillamineinduced neuromyotonia. British Medical Journal, 1, 1464-1465. doi:10.1136/bmj.1.6176.1464
[10] Hart, I.K., Waters, C., Vincent, A., Newland, C., Beeson, D., Pongs, O., et al. (1997) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Annals of Neurology, 41, 238-246.
[11] Nagado, T., Arimura, K., Sonoda, Y., Kurono, A., Horikiri, Y., Kameyama, A., et al. (1999) Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain, 122, 2057-2066. doi:10.1093/brain/122.11.2057
[12] Mitchell, P.L., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., et al. (2006) Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clinical Colorectal Cancer, 6, 146-151. doi:10.3816/CCC.2006.n.032
[13] Frampton, J.E. and Foster, R.H. (2005) Pregabalin in the treatment of postherpetic neuralgia. Drugs, 65, 111-120.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.